Interferon Alpha-2a for the Treatment of Post-Infectious Uveitis Secondary to Presumed Intraocular Tuberculosis

Ocular Immunology and Inflammation
Alessandro InvernizziLuca Cimino

Abstract

Purpose: To assess the efficacy and tolerability of interferon (IFN) alpha-2a in post-infectious uveitis secondary to presumed intraocular tuberculosis (IOTB). Methods: Patients with chronic uveitis secondary to presumed IOTB who, after completing an antitubercular treatment, showed poor response to treatments or recurred after tapering oral corticosteroids to ≤7.5 mg/day were enrolled. All patients were treated with IFN alpha-2a subcutaneous injections. Best-corrected visual acuity (BCVA), central retinal thickness (CRT), and inflammatory signs were compared between baseline and follow-up visits up to six months. Results: Twelve eyes (six patients) were enrolled. Mean BCVA improved from 0.64 ± 0.55 logMAR at baseline to 0.32 ± 0.31 logMAR at 6 months (p = 0.03). Mean CRT decreased from 372 ± 132.2 μm to 274.66 ± 34.9 μm at six months (p = 0.01). Inflammatory signs (vitritis, vasculitis) also decreased overtime. No major complications or tuberculosis reactivations were recorded. Conclusions: IFN alpha-2a was efficacious and safe in treating chronic post-infectious uveitis secondary to presumed IOTB.

References

Jul 22, 1998·Journal of Hepatology·R M HoffmannG R Pape
Oct 1, 2005·American Journal of Ophthalmology·Douglas A JabsUNKNOWN Standardization of Uveitis Nomenclature (SUN) Working Group
Nov 22, 2007·Survey of Ophthalmology·Vishali GuptaNarsing A Rao
Aug 19, 2008·American Journal of Ophthalmology·Reema BansalSunil Kumar Arora
Jan 25, 2012·Rheumatology·Guillermo Ruiz-IrastorzaMunther Khamashta
Mar 14, 2012·Ocular Immunology and Inflammation·Nicholas J ButlerJames T Rosenbaum
Mar 21, 2015·European Journal of Ophthalmology·Zhuyun QianPhuc LeHoang
Oct 12, 2016·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Jae Hyung LeeSung Eun Kim
Dec 10, 2016·Ocular Immunology and Inflammation·Emmett T CunninghamManfred Zierhut
Mar 16, 2017·BMC Ophthalmology·Yoshiro MinamiAkitoshi Yoshida
Apr 18, 2017·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Merih OrayIlknur Tugal-Tutkun

❮ Previous
Next ❯

Citations

Apr 6, 2019·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Natalia LewczukJoanna Bogusławska
Dec 11, 2019·Ocular Immunology and Inflammation·Chloé CouretMichel Weber
May 21, 2019·Ocular Immunology and Inflammation·L De SimoneL Cimino
Oct 14, 2018·Eye·Aniruddha AgarwalVishali Gupta
Jul 4, 2020·International Ophthalmology·Rohan Bir SinghAniruddha Agarwal
Jan 23, 2021·Asia-Pacific Journal of Ophthalmology·Lisia Barros FerreiraJustine R Smith
Aug 5, 2021·Ocular Immunology and Inflammation·Nihan Aksu-CeylanIlknur Tugal-Tutkun

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.